Medistim ASA (STU:MD1) Research & Development: €0.00 Mil (TTM As of Mar. 2026)


STU:MD1 Medistim ASA STU:MD1
96 GF Score
Price €20.10
GF Value €22.51
! 1 Warning Sign
View Full Analysis

What is Medistim ASA Research & Development?

Medistim ASA STU:MD1 -0.99% 96 Research & Development is €0.00 Mil as of Mar. 2026. GuruFocus rates STU:MD1 with a GF Score™ of 96/100 and a GF Value™ of €22.51. The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Medistim ASA's Research & Development for the three months ended in Mar. 2026 was €0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €0.00 Mil.

Medistim ASA  (STU:MD1) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Medistim ASA Research & Development Related Terms

Medistim ASA Research & Development Historical Data

* Premium members only.

The historical data trend for Medistim ASA's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medistim ASA Research & Development Chart

Medistim ASA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Medistim ASA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STU:MD1
96GF Score
Medistim ASA STU:MD1
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medistim ASA Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0.00 Mil mean?
Medistim ASA (STU:MD1) has a Research & Development of €0.00 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Medistim ASA and its competitors.
Is Medistim ASA's Research & Development too high?
Medistim ASA's current Research & Development is €0.00 Mil. Overall, Medistim ASA has a GF Score™ of 96/100, reflecting its overall financial health beyond just this single metric.
How does Medistim ASA's Research & Development compare to ABT and SYK?
Medistim ASA's Research & Development of €0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Medistim ASA and its competitors. Medistim ASA's current Research & Development is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medistim ASA stock overvalued right now?
Medistim ASA (STU:MD1) has a current Research & Development of €0.00 Mil. The stock's GF Value™ is €22.51, compared to a current price of €20.10 — trading 10.7% below its estimated fair value. The current Research & Development is €0.00 Mil. Medistim ASA's overall GF Score™ is 96/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Medistim ASA (STU:MD1), the current Research & Development is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medistim ASA (STU:MD1) Overvalued in 2026?

Based on GuruFocus' analysis, Medistim ASA stock appears to be undervalued. The current stock price of €20.10 is trading 10.7% below its estimated GF Value™ of €22.51.

Key valuation signals for STU:MD1:

  • Research & Development: €0.00 Mil
  • GF Value™: €22.51 vs. price of €20.10 (10.7% below fair value)
  • GF Score™: 96/100 with 1 warning sign

No single metric tells the full story. See the STU:MD1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medistim ASA Business Description

Address Okernveien 94, Oslo, NOR, 0579
Medistim ASA is a medical device company. It is engaged in researching, developing, producing, distributing, and sales of medical equipment through its own business or participation in other companies, as well as related activities. The company's business is focused on cardiac and vascular surgery. The group operates in the USA, Europe, China, and the Rest of the World. The main divisions are sale of own products and sale of third-party products. Sale of own products has two business models, the capital model and the lease model. Third-party products segment sells medical devices from third party manufacturers in Norway, Sweden and Denmark. Key revenue is generated from Own Products segment.
96GF Score

Get the complete analysis for STU:MD1

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€20.10
Price
€22.51
GF Value